J
Junming Zhu
Researcher at ImClone Systems
Publications - 2
Citations - 1894
Junming Zhu is an academic researcher from ImClone Systems. The author has contributed to research in topics: Survival analysis & Clinical endpoint. The author has an hindex of 2, co-authored 2 publications receiving 1747 citations.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
James A. Bonner,Paul M. Harari,Jordi Giralt,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,José Baselga,Sharon A. Spencer,Junming Zhu,Hagop Youssoufian,Eric K. Rowinsky,K. Kian Ang +12 more
TL;DR: Overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients.
Journal ArticleDOI
A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Bart C. Kuenen,Petronella O. Witteveen,Rita Ruijter,Giuseppe Giaccone,Aruna Dontabhaktuni,Floyd Fox,Terry Katz,Hagop Youssoufian,Junming Zhu,Eric K. Rowinsky,Emile E. Voest +10 more
TL;DR: Well tolerated, necitumumab is associated with preliminary evidence of antitumor activity, and achieves biologically relevant concentrations throughout the dosing period, and the recommended dose for further clinical development is 800 mg (flat dose) weekly or every 2 weeks based on the clinical setting.